A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., Han, T. H., Sievers, E. L., Bartlett, N. L.Volume:
18
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-11-1425
Date:
January, 2012
File:
PDF, 267 KB
english, 2012